Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Dr. Reddy’s Laboratories, along with its subsidiaries (together referred to as “Dr. Reddy’s”) announced the launch of Dr. Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar® (sorafenib) Tablets in the U.S. market, following the approval by the U.S. Food and Drug Administration (USFDA).
read more
According to the new market research report "Pharmaceutical Excipients Market by Product, the Pharmaceutical Excipients Market is projected to reach $11.5B by 2027 from $8.6B in 2022, at a CAGR of 5.9% during the forecast period of 2022 to 2027.
read more
The active pharmaceutical ingredients (API) market size is expected to grow by $64.53B from 2020 to 2025, progressing at a CAGR of 6.1% according to the latest market research report by Technavio– with 66% of the market's growth originating from Asia-Pacific countries (APAC) during the forecast period.
read more
The pharmaceuticals wholesale and distribution market is expected to grow by $548.7M from 2020 to 2025. Moreover, the growth momentum of the market will accelerate at a CAGR of 7.93% during the forecast period, according to a report by Technavio.
read more
Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, U.S. affiliates of Teva Pharmaceutical Industries, have reached an agreement with Aurobindo to resolve the dispute over Aurobindo’s Abbreviated New Drug Application (“ANDA") for a generic deutetrabenazine product.
read more
The prevalence and incidence of cardiovascular conditions in developed economies continue to increase, creating challenges and opportunities for cardiovascular drug developers.
read more
Accord Healthcare, a generic pharmaceutical company, has added Vilazodone to its oral tablets portfolio.
read more
The herpes zoster therapeutics market is fragmented, and the vendors are deploying growth strategies such as focusing on expanding their business activities in developed and rapidly emerging markets by launching products to compete in the market, according to a report from Technavio.
read more
Pfizer announced that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets).
read more
A report, by Research & Markets, about 3D printing (also called “additive manufacturing”), discusses how the technology–often used in tissue engineering–could be applied to drug production.
read more
ANI Pharmaceuticals announced U.S. Food and Drug Administration approval for the Abbreviated New Drug Application (ANDA) for Fludrocortisone Acetate Tablets USP, 0.1 mg.
read more
A report by Technavio predicts the empty capsules market will witness a potential growth of $1.10B from 2021 to 2026. The market is also anticipated to project an accelerating growth momentum at a CAGR of 7.3% during this period.
read more
Mezzion Pharma met with the FDA Division of Cardiology and Nephrology (DCN) May 27 to discuss with the FDA the path forward for the regulatory approval of udenafil for the treatment of single ventricle heart disease (SVHD) in children with Fontan physiology.
read more
The Global Pharmaceutical Manufacturing Market size was estimated at $454.02B in 2021, $509.45B in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 12.38% to reach $914.90By 202, according to a Research & Markets report.
read more
AbbVie announced results from three Phase 3 clinical trials – U-ACHIEVE (induction), U-ACCOMPLISH and U-ACHIEVE (maintenance) – evaluating upadacitinib (RINVOQ®) in patients with moderately to severely active ulcerative colitis who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.
read more